{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T03:38:56Z","timestamp":1772941136612,"version":"3.50.1"},"reference-count":73,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010256","name":"Guangzhou Municipal Science and Technology Project","doi-asserted-by":"publisher","award":["201804010027"],"award-info":[{"award-number":["201804010027"]}],"id":[{"id":"10.13039\/501100010256","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373874"],"award-info":[{"award-number":["82373874"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82404634"],"award-info":[{"award-number":["82404634"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81773740"],"award-info":[{"award-number":["81773740"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173825"],"award-info":[{"award-number":["82173825"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.phrs.2025.107903","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T15:16:32Z","timestamp":1755098192000},"page":"107903","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Osteoclast precursor cell-derived Flot2 is a novel therapeutic target for bone loss diseases"],"prefix":"10.1016","volume":"219","author":[{"given":"Binhua","family":"Zou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiehuang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weili","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lihong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziye","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qinghe","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wende","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2668-3044","authenticated-orcid":false,"given":"Xiaojuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2025.107903_bib1","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.cell.2021.02.002","article-title":"Osteoclasts recycle via osteomorphs during RANKL-stimulated bone resorption","volume":"184","author":"McDonald","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2025.107903_bib2","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41413-022-00190-4","article-title":"Mechanical regulation of bone remodeling","volume":"10","author":"Wang","year":"2022","journal-title":"Bone Res"},{"key":"10.1016\/j.phrs.2025.107903_bib3","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1152\/physrev.00012.2019","article-title":"Bone metastasis: mechanisms, therapies, and biomarkers","volume":"101","author":"Clezardin","year":"2021","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.phrs.2025.107903_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107682","article-title":"RANKL as a key figure in bridging between the bone and immune system: its physiological functions and potential as a pharmacological target","volume":"218","author":"Honma","year":"2021","journal-title":"Pharm. Ther."},{"key":"10.1016\/j.phrs.2025.107903_bib5","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.pharmthera.2017.02.017","article-title":"Macrophages and skeletal health","volume":"174","author":"Michalski","year":"2017","journal-title":"Pharm. Ther."},{"key":"10.1016\/j.phrs.2025.107903_bib6","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature01658","article-title":"Osteoclast differentiation and activation","volume":"423","author":"Boyle","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2025.107903_bib7","doi-asserted-by":"crossref","unstructured":"Takayanagi H. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol 202-07;7:292-304. https:\/\/doi.org\/10.1038\/nri2062.","DOI":"10.1038\/nri2062"},{"key":"10.1016\/j.phrs.2025.107903_bib8","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41413-023-00296-3","article-title":"Trim21 depletion alleviates bone loss in osteoporosis via activation of YAP1\/\u03b2-catenin signaling","volume":"11","author":"Liu","year":"2023","journal-title":"Bone Res"},{"key":"10.1016\/j.phrs.2025.107903_bib9","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/nrendo.2013.137","article-title":"Osteopetrosis: genetics, treatment and new insights into osteoclast function","volume":"9","author":"Sobacchi","year":"2013","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.phrs.2025.107903_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2020.153377","article-title":"Kirenol inhibits RANKL-induced osteoclastogenesis and prevents ovariectomized-induced osteoporosis via suppressing the Ca(2+)-NFATc1 and Cav-1 signaling pathways","volume":"80","author":"Zou","year":"2021","journal-title":"Phytomedicine"},{"key":"10.1016\/j.phrs.2025.107903_bib11","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/s41401-020-0477-4","article-title":"Oridonin ameliorates inflammation-induced bone loss in mice via suppressing DC-STAMP expression","volume":"42","author":"Zou","year":"2021","journal-title":"Acta Pharm. Sin."},{"key":"10.1016\/j.phrs.2025.107903_bib12","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41413-023-00257-w","article-title":"New insights into inflammatory osteoclast precursors as therapeutic targets for rheumatoid arthritis and periodontitis","volume":"11","author":"Emilie","year":"2023","journal-title":"Bone Res"},{"key":"10.1016\/j.phrs.2025.107903_bib13","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/S2213-8587(17)30188-2","article-title":"Osteoporosis treatment: recent developments and ongoing challenges","volume":"5","author":"Khosla","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.phrs.2025.107903_bib14","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ctrv.2018.06.007","article-title":"Medication-related osteonecrosis of the jaw: prevention, diagnosis and management in patients with cancer and bone metastases","volume":"69","author":"Otto","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.phrs.2025.107903_bib15","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S2213-8587(18)30047-0","article-title":"Bone health during endocrine therapy for cancer","volume":"6","author":"Rachner","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.phrs.2025.107903_bib16","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1111\/bcp.13759","article-title":"Side effects of drugs for osteoporosis and metastatic bone disease","volume":"85","author":"Skjodt","year":"2019","journal-title":"Br. J. Clin. Pharm."},{"key":"10.1016\/j.phrs.2025.107903_bib17","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nrc3055","article-title":"Cancer to bone: a fatal attraction","volume":"11","author":"Weilbaecher","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.phrs.2025.107903_bib18","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0140-6736(18)32112-3","article-title":"Osteoporosis","volume":"393","author":"Compston","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2025.107903_bib19","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41572-020-00216-3","article-title":"Bone metastases","volume":"6","author":"Coleman","year":"2020","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.phrs.2025.107903_bib20","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S0140-6736(21)02646-5","article-title":"Drug therapy for osteoporosis in older adults","volume":"399","author":"Reid","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2025.107903_bib21","doi-asserted-by":"crossref","first-page":"182","DOI":"10.7326\/M22-0684","article-title":"Effectiveness and safety of treatments to prevent fractures in people with low bone mass or primary osteoporosis: a living systematic review and network Meta-analysis for the American college of physicians","volume":"176","author":"Chelsea","year":"2023","journal-title":"Ann. Intern Med"},{"key":"10.1016\/j.phrs.2025.107903_bib22","article-title":"Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials","volume":"381","author":"Mina Nicole","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.phrs.2025.107903_bib23","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.phrs.2019.02.015","article-title":"Sinomenine inhibits osteolysis in breast cancer by reducing IL-8\/CXCR1 and c-Fos\/NFATc1 signaling","volume":"142","author":"Zhang","year":"2019","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2025.107903_bib24","doi-asserted-by":"crossref","DOI":"10.1172\/JCI140214","article-title":"Bone marrow adipogenic lineage precursors promote osteoclastogenesis in bone remodeling and pathologic bone loss","volume":"131","author":"Yu","year":"2021","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.phrs.2025.107903_bib25","doi-asserted-by":"crossref","DOI":"10.2991\/978-94-6463-556-0","article-title":"Erianin serves as an NFATc1 inhibitor to prevent breast cancer-induced osteoclastogenesis and bone destruction","volume":"30","author":"Zheng","year":"2024","journal-title":"J. Adv. Res"},{"issue":"5","key":"10.1016\/j.phrs.2025.107903_bib26","doi-asserted-by":"crossref","DOI":"10.1038\/s41596-020-0312-x","article-title":"The HDOCK server for integrated protein-protein docking","volume":"15","author":"Yan","year":"2020","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.phrs.2025.107903_bib27","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","article-title":"Highly accurate protein structure prediction with AlphaFold","volume":"596","author":"Jumper","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2025.107903_bib28","doi-asserted-by":"crossref","DOI":"10.1038\/emm.2015.77","article-title":"Caveolin-1 regulates osteoclast differentiation by suppressing cfms degradation","volume":"47","author":"Lee","year":"2015","journal-title":"Exp. Mol. Med"},{"key":"10.1016\/j.phrs.2025.107903_bib29","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1146\/annurev-physiol-021119-034332","article-title":"The osteocyte: new insights","volume":"82","author":"Robling","year":"2020","journal-title":"Annu Rev. Physiol."},{"key":"10.1016\/j.phrs.2025.107903_bib30","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41413-023-00277-6","article-title":"Identification of an intronic enhancer regulating RANKL expression in osteocytic cells","volume":"11","author":"Yan","year":"2023","journal-title":"Bone Res"},{"key":"10.1016\/j.phrs.2025.107903_bib31","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.7150\/thno.30206","article-title":"Pseurotin a inhibits osteoclastogenesis and prevents Ovariectomized-Induced bone loss by suppressing reactive oxygen species","volume":"9","author":"Chen","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.phrs.2025.107903_bib32","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ccr.2006.08.025","article-title":"Targeting b2-microglobulin for induction of tumor apoptosis in human hematological malignancies","volume":"10","author":"Yang","year":"2006","journal-title":"Cancer Cell"},{"key":"10.1016\/j.phrs.2025.107903_bib33","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1016\/j.cub.2022.06.038","article-title":"Src activation in lipid rafts confers epithelial cells with invasive potential to escape from apical extrusion during cell competition","volume":"32","author":"Kajiwara","year":"2022","journal-title":"Curr. Biol."},{"key":"10.1016\/j.phrs.2025.107903_bib34","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41413-021-00158-w","article-title":"Inflammatory conversion of quiescent osteoblasts by metastatic breast cancer cells through pERK1\/2 aggravates cancer-induced bone destruction","volume":"9","author":"Back","year":"2021","journal-title":"Bone Res"},{"issue":"1","key":"10.1016\/j.phrs.2025.107903_bib35","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/aps.2013.152","article-title":"Plumbagin attenuates cancer cell growth and osteoclast formation in the bone microenvironment of mice","volume":"35","author":"Yan","year":"2014","journal-title":"Acta Pharm. Sin."},{"key":"10.1016\/j.phrs.2025.107903_bib36","doi-asserted-by":"crossref","DOI":"10.1172\/JCI154888","article-title":"Cellular senescence and the skeleton: pathophysiology and therapeutic implications","volume":"132","author":"Khosla","year":"2022","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.phrs.2025.107903_bib37","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/164_2020_373","article-title":"Osteoporosis therapeutics 2020","volume":"262","author":"Kocijan","year":"2020","journal-title":"Handb. Exp. Pharm."},{"key":"10.1016\/j.phrs.2025.107903_bib38","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1021\/acs.jmedchem.0c01292","article-title":"Bisphosphonates, old friends of bones and new trends in clinics","volume":"64","author":"Barbosa","year":"2021","journal-title":"J. Med Chem."},{"key":"10.1016\/j.phrs.2025.107903_bib39","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.bone.2010.11.020","article-title":"Denosumab and bisphosphonates: different mechanisms of action and effects","volume":"48","author":"Baron","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.phrs.2025.107903_bib40","doi-asserted-by":"crossref","first-page":"8","DOI":"10.11005\/jbm.2014.21.1.8","article-title":"Bone biology and anabolic therapies for bone: current status and future prospects","volume":"21","author":"Martin","year":"2014","journal-title":"J. Bone Metab."},{"key":"10.1016\/j.phrs.2025.107903_bib41","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1210\/jc.2004-2126","article-title":"Effect of L-000845704, an alphaVbeta3 integrin antagonist, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women","volume":"90","author":"Murphy","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.phrs.2025.107903_bib42","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1210\/er.2015-1114","article-title":"Cathepsin k inhibitors for osteoporosis: biology, potential clinical utility, and lessons learned","volume":"38","author":"Drake","year":"2017","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.phrs.2025.107903_bib43","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1186\/1743-422X-8-479","article-title":"Research advances on flotillins","volume":"8","author":"Zhao","year":"2011","journal-title":"Virol. J."},{"key":"10.1016\/j.phrs.2025.107903_bib44","doi-asserted-by":"crossref","first-page":"7361","DOI":"10.1158\/0008-5472.CAN-04-0823","article-title":"Up-regulation of Flotillin-2 is associated with melanoma progression and modulates expression of the thrombin receptor protease activated receptor 1","volume":"64","author":"Hazarika","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.phrs.2025.107903_bib45","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/1479-5876-11-190","article-title":"Flotillin-2 is associated with breast cancer progression and poor survival outcomes","volume":"11","author":"Wang","year":"2013","journal-title":"J. Transl. Med."},{"issue":"1","key":"10.1016\/j.phrs.2025.107903_bib46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/19336918.2023.2260641","article-title":"Knockdown of PAF1 reduces cervical cancer cell proliferation, migration and invasion via retarding FLOT2-mediated MEK\/ERK1\/2 pathway","volume":"17","author":"Tang","year":"2023","journal-title":"Cell Adhes. Migr."},{"issue":"1","key":"10.1016\/j.phrs.2025.107903_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/21655979.2019.1586056","article-title":"MicroRNA-485-5p suppresses the proliferation, migration and invasion of small cell lung cancer cells by targeting flotillin-2","volume":"10","author":"Gao","year":"2019","journal-title":"Bioengineered"},{"key":"10.1016\/j.phrs.2025.107903_bib48","first-page":"2802","article-title":"FLOT2 overexpression is associated with the progression and prognosis of human colorectal cancer","volume":"17","author":"Li","year":"2019","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.phrs.2025.107903_bib49","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1359\/jbmr.060308","article-title":"RANKL-induced expression of tetraspanin CD9 in lipid raft membrane microdomain is essential for cell fusion during osteoclastogenesis","volume":"21","author":"Masaru","year":"2006","journal-title":"J. Bone Min. Res."},{"key":"10.1016\/j.phrs.2025.107903_bib50","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1007\/s00774-009-0150-y","article-title":"Proteomic analysis of osteoclast lipid rafts: the role of the integrity of lipid rafts on V-ATPase activity in osteoclasts","volume":"28","author":"Jiyoon","year":"2010","journal-title":"J. Bone Min. Metab."},{"key":"10.1016\/j.phrs.2025.107903_bib51","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1172\/JCI59987","article-title":"Glycosphingolipid synthesis inhibition limits osteoclast activation and myeloma bone disease","volume":"125","author":"Ersek","year":"2015","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.phrs.2025.107903_bib52","doi-asserted-by":"crossref","first-page":"6522","DOI":"10.1074\/jbc.M114.598581","article-title":"Caveolin-1 regulates osteoclastogenesis and bone metabolism in a sex-dependent manner","volume":"290","author":"Lee","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2025.107903_bib53","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41419-019-1353-3","article-title":"TRAIL inhibits RANK signaling and suppresses osteoclast activation via inhibiting lipid raft assembly and TRAF6 recruitment","volume":"10","author":"Liao","year":"2019","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.phrs.2025.107903_bib54","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1002\/med.21842","article-title":"The immunosuppressive activity of artemisinin-type drugs towards inflammatory and autoimmune diseases","volume":"41","author":"Efferth","year":"2021","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.phrs.2025.107903_bib55","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1600-065X.2009.00821.x","article-title":"Ca2+-NFATc1 signaling is an essential axis of osteoclast differentiation","volume":"231","author":"Negishi-Koga","year":"2009","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.phrs.2025.107903_bib56","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jconrel.2022.01.012","article-title":"RNA interference (RNAi)-based plasmonic nanomaterials for cancer diagnosis and therapy","volume":"342","author":"Yoon","year":"2022","journal-title":"J. Control. Release Off. J. Control. Release Soc."},{"key":"10.1016\/j.phrs.2025.107903_bib57","doi-asserted-by":"crossref","first-page":"12181","DOI":"10.1021\/acs.chemrev.1c00244","article-title":"Lipids and lipid derivatives for RNA delivery","volume":"20","author":"Zhang","year":"2021","journal-title":"Chem. Rev."},{"key":"10.1016\/j.phrs.2025.107903_bib58","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41392-023-01690-3","article-title":"Targeting proprotein convertase subtilisin\/kexin type 9 (PCSK9): from bench to bedside","volume":"9","author":"Bao","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.phrs.2025.107903_bib59","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/s41591-021-01664-4","article-title":"AAV gene therapy for Tay-Sachs disease","volume":"28","author":"Flotte","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.phrs.2025.107903_bib60","first-page":"1","article-title":"Etranacogene dezaparvovec for the treatment of adult patients with severe and moderately severe hemophilia b","volume":"27","author":"Castaman","year":"2023","journal-title":"Expert Rev. Hematol."},{"key":"10.1016\/j.phrs.2025.107903_bib61","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s40265-023-01845-0","article-title":"Etranacogene dezaparvovec: first approval","volume":"83","author":"Heo","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2025.107903_bib62","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41584-023-00935-3","article-title":"Mechanisms underlying the long-term and withdrawal effects of denosumab therapy on bone","volume":"19","author":"Ferrari","year":"2023","journal-title":"Nat. Rev. Rheuma"},{"key":"10.1016\/j.phrs.2025.107903_bib63","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1078\/0171-2985-00114","article-title":"The lipid raft microdomain-associated protein reggie-1\/flotillin-2 is expressed in human b cells and localized at the plasma membrane and centrosome in PBMCs","volume":"205","author":"Solomon","year":"2022","journal-title":"Immunobiology"},{"key":"10.1016\/j.phrs.2025.107903_bib64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11307-018-1181-3","article-title":"The evolving role of FDG-PET\/CT in the diagnosis, staging, and treatment of breast cancer","volume":"21","author":"Paydary","year":"2019","journal-title":"Mol. Imaging Biol."},{"key":"10.1016\/j.phrs.2025.107903_bib65","article-title":"Review of breast cancer pathologigcal image processing","volume":"2021","author":"Zhang","year":"2021","journal-title":"Biomed. Res Int"},{"key":"10.1016\/j.phrs.2025.107903_bib66","first-page":"310","article-title":"Microcalcifications in breast cancer: from pathophysiology to diagnosis and prognosis","volume":"1869","author":"Grady","year":"2018","journal-title":"Bba Rev. Cancer"},{"key":"10.1016\/j.phrs.2025.107903_bib67","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/cge.13514","article-title":"Liquid biopsy in breast cancer: a comprehensive review","volume":"95","author":"Alimirzaie","year":"2019","journal-title":"Clin. Genet"},{"key":"10.1016\/j.phrs.2025.107903_bib68","doi-asserted-by":"crossref","first-page":"e279","DOI":"10.1016\/S1470-2045(13)70567-9","article-title":"Breast cancer in China","volume":"15","author":"Fan","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.phrs.2025.107903_bib69","first-page":"17","article-title":"Epidemiology and management of osteoporosis in the people's republic of China: current perspectives","volume":"10","author":"Lin","year":"2015","journal-title":"Clin. Inter. Aging"},{"key":"10.1016\/j.phrs.2025.107903_bib70","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13058-016-0736-y","article-title":"Breast cancer biologic and etiologic heterogeneity by young age and menopausal status in the carolina breast cancer study: a case-control study","volume":"18","author":"Chollet-Hinton","year":"2016","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.phrs.2025.107903_bib71","first-page":"63","article-title":"Interpretation on the global cancer statistics of GLOBOCAN 2020","volume":"13","author":"Cao","year":"2021","journal-title":"Chin. J. Front Med Sci. Electron Version"},{"issue":"2","key":"10.1016\/j.phrs.2025.107903_bib72","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1803164","article-title":"Tailoring adjuvant endocrine therapy for premenopausal breast cancer","volume":"379","author":"Francis","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2025.107903_bib73","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1186\/s13058-014-0427-5","article-title":"Biology of breast cancer in young women","volume":"16","author":"Partridge","year":"2014","journal-title":"Breast Cancer Res."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661825003287?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661825003287?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T10:49:07Z","timestamp":1772880547000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661825003287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":73,"alternative-id":["S1043661825003287"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2025.107903","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Osteoclast precursor cell-derived Flot2 is a novel therapeutic target for bone loss diseases","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2025.107903","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107903"}}